Orbimed Advisors Llc Sells 235,863 Shares of Sionna Therapeutics (NASDAQ:SION) Stock

Key Points

• Orbimed Advisors LLC sold a total of about 541,536 shares of Sionna Therapeutics across recent trades (including 235,863 shares on April 15) for roughly $24.3 million, reducing its stake by 6.77% to 3,247,025 shares; the April 15 sale was executed under a pre‑arranged Rule 10b5‑1 plan.
• Sionna shares traded up modestly to $45.24 on heavy volume, the company beat quarterly EPS estimates (‑$0.46 vs. ‑$0.61 expected), and analysts remain largely positive with a consensus rating of “Moderate Buy” and a consensus target of about $50.57 (individual targets up to $58).

Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) Director Orbimed Advisors Llc sold 235,863 shares of the stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $44.64, for a total value of $10,528,924.32. Following the sale, the director owned 3,247,025 shares of the company's stock, valued at $144,947,196. This trade represents a 6.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Orbimed Advisors Llc also recently made the following trade(s):

• On Thursday, April 16th, Orbimed Advisors Llc sold 226,906 shares of Sionna Therapeutics stock. The stock was sold at an average price of $45.34, for a total transaction of $10,287,918.04.
• On Tuesday, April 14th, Orbimed Advisors Llc sold 47,814 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.51, for a total transaction of $2,128,201.14.
• On Tuesday, February 3rd, Orbimed Advisors Llc sold 29,063 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.58, for a total transaction of $1,295,628.54.
• On Monday, February 2nd, Orbimed Advisors Llc sold 1,890 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.57, for a total transaction of $84,237.30.

Sionna Therapeutics Stock Up 0.3%

SION stock traded up $0.15 during mid-day trading on Thursday, reaching $45.24. 817,609 shares of the stock traded hands, compared to its average volume of 382,339. Sionna Therapeutics, Inc. has a 52 week low of $9.39 and a 52 week high of $46.10. The business has a 50-day moving average of $37.40 and a two-hundred day moving average of $38.18.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last released its quarterly earnings results on Monday, March 2nd. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.61) by $0.15.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Lifesci Capital upgraded shares of Sionna Therapeutics to a "strong-buy" rating in a research note on Wednesday, February 25th. Guggenheim increased their target price on shares of Sionna Therapeutics from $45.00 to $50.00 and gave the company a "buy" rating in a research note on Monday, March 2nd. Raymond James Financial reaffirmed a "strong-buy" rating and set a $53.00 price objective on shares of Sionna Therapeutics in a report on Monday, January 5th. BTIG Research reaffirmed a "buy" rating and set a $58.00 price objective on shares of Sionna Therapeutics in a report on Monday, March 2nd. Finally, Citigroup initiated coverage on shares of Sionna Therapeutics in a report on Tuesday, February 24th. They set an "outperform" rating for the company. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $50.57.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of SION. Goldman Sachs Group Inc. acquired a new stake in Sionna Therapeutics during the 1st quarter worth $667,000. Woodline Partners LP bought a new position in Sionna Therapeutics in the 1st quarter valued at about $837,000. Geode Capital Management LLC raised its holdings in Sionna Therapeutics by 113.4% in the 2nd quarter. Geode Capital Management LLC now owns 289,275 shares of the company's stock valued at $5,020,000 after acquiring an additional 153,712 shares during the period. Rhumbline Advisers bought a new position in Sionna Therapeutics in the 2nd quarter valued at about $307,000. Finally, New York State Common Retirement Fund bought a new position in Sionna Therapeutics in the 2nd quarter valued at about $118,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.